98%
921
2 minutes
20
Objective: To investigate the changes of dynamic contrast-enhanced MR imaging (DCE-MRI) parameters at 3 T in cervical cancer patients before and after concurrent chemoradiotherapy (CCRT), and to correlate the parameters with final tumour response to therapy.
Methods: Thirty-five patients with cervical cancer underwent DCE-MRI before CCRT, 4 weeks after starting therapy and at 1 month after the end of therapy. DCE-MRI parameters were calculated in the tumour and normal gluteus muscle. Final response to treatment as determined by changes in tumour size and volume was correlated with pre-treatment DCE-MRI parameters.
Results: DCE-MRI parameters (i.e. K (trans), v (e) and k (ep)) in the tumours showed significant changes in response to CCRT (P < 0.05) and in particular K (trans) and v (e) demonstrated early significant increase (P < 0.01), but those in normal muscle did not show a significant difference (P > 0.05). Before therapy, the mean values of K (trans), k (ep), v (e) and v (p) in the tumours were significantly greater than those in muscle (P < 0.05). DCE-MRI parameters of the tumours at pre-treatment were not statistically associated with final tumour size or volume change.
Conclusion: DCE-MRI parameters may help evaluate early changes of cervical cancer to CCRT, but larger, more definitive studies are needed.
Key Points: • DCE-MRI offers new insights into tumour behaviour. • Changes in tumour size lag behind biomarkers which improve quickly in responders. • DCE-MRI is a non-invasive imaging technique that can characterize tumour vasculature. • DCE-MRI of cervical cancer may be useful in monitoring changes with therapy.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00330-012-2504-4 | DOI Listing |
Int J Gen Med
September 2025
Suzhou Medical College of Soochow University, Suzhou, Jiangsu, People's Republic of China.
Purpose: The fourth most common cause of cancer-related deaths in women is cervical cancer. Though treatment of early-stage cervical cancer is often effective, middle and advanced stage cervical cancer is hard to treat and prone to recurrence. We sought to explore the mechanism underlying cervical cancer progression to identify new therapeutic approaches.
View Article and Find Full Text PDFFront Immunol
September 2025
Department of Medicine, Division of Hematology, Bioclinicum and Center for Molecular Medicine, Karolinska Institute and Karolinska University Hospital Solna, Stockholm, Sweden.
Background: Metabolic reprogramming is an important hallmark of cervical cancer (CC), and extensive studies have provided important information for translational and clinical oncology. Here we sought to determine metabolic association with molecular aberrations, telomere maintenance and outcomes in CC.
Methods: RNA sequencing data from TCGA cohort of CC was analyzed for their metabolic gene expression profile and consensus clustering was then performed to classify tumors into different groups/subtypes.
Front Microbiol
August 2025
Department of Immunology, School of Medicine, Kyungpook National University, Daegu, Republic of Korea.
The genus is a heterogenous group of commensal and pathogenic bacteria. Members of this genus are classified into two major groups, the pyogenic group and the viridans group streptococci (VGS). VGS are frequently found as normal members of the human microbiome and are regarded as commensals.
View Article and Find Full Text PDFBiochem Biophys Rep
June 2025
The Affiliated Traditional Chinese Medicine Hospital, Guangzhou Medical University, Guangzhou, Guangdong Province, China.
Background: SLC16A3, a highly expressed H + -coupled symporter, facilitates lactate transport via monocarboxylate transporters (MCTs), contributing to acidosis. Although SLC16A3 has been implicated in tumor development, its role in tumor immunity remains unclear.
Methods: A pan-cancer analysis was conducted using datasets from The Cancer Genome Atlas, Cancer Cell Line Encyclopedia, and Genotype-Tissue Expression projects.
Surg Case Rep
September 2025
Department of Surgery and Science, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Toyama, Japan.
Introduction: There are no reports of patients undergoing McKeown esophagectomy for esophageal cancer after undergoing pancreaticoduodenectomy for pancreatic cancer. We report the case of a patient who underwent subtotal esophagectomy and colon reconstruction after pancreaticoduodenectomy using the mesenteric approach.
Case Presentation: A 71-year-old male was diagnosed with advanced esophageal cancer.